APOGEPHA

What APOGEPHA does

APOGEPHA Arzneimittel GmbH is a family-owned German pharmaceutical company headquartered in Dresden that develops, markets, and distributes prescription and pharmacy-exclusive products focused on urology and uro-oncology. The portfolio spans benign prostatic hyperplasia (APOPROSTAT forte, a high-dose phytosterol preparation), prostatitis (PROSTUROL suppositories with hyaluronic acid and plant-based ingredients), bladder cancer immunotherapy (BCG Apogepha, intravesical Bacillus Calmette-Guérin from the Brazilian Moreau substrain), and chemotherapy-induced neutropenia prophylaxis (Ryzneuta / Efbemalenograstim alfa, a long-acting non-pegylated G-CSF). Dietary supplements such as FEMALAC (D-mannose plus lactobacilli) address adjacent urinary tract health needs, and the company also promotes Digital Health Applications (DiGAs) including kontina and Uroletics for bladder training and prostate cancer rehabilitation.

The company's origins date to 1882, with its modern form established under family ownership after Dr. Christian Starke's 1991 reprivatization - one of the first such transactions in the reunified German federal states. Distribution is pharmacy-exclusive in Germany, executed through a qualified field sales force that delivers scientifically grounded product information to urologists and oncologists, supported by statutory health insurance discount agreements (notably with Techniker Krankenkasse for Ryzneuta from December 2025). Marketing and medical-education engagement centers on recurring event-driven activity including the long-running Dresdner Urologentag (30th edition, November 2025), SWDGU congress, Urologisches Winterforum Großhadern, and Urologinnen Treffen, complemented by the bi-monthly Wissensdrang newsletter for healthcare professionals.

The operating model is that of a regulated Mittelstand specialty pharmaceutical: GMP-compliant manufacturing oversight by Landesdirektion Sachsen, a wholesale license, dedicated pharmacovigilance infrastructure, and an ecosystem that extends from KOL engagement (NRWGU Dr. Richard Berges-Preis) to academic sponsorships (Universität Leipzig Deutschlandstipendien since 2012). Around 150 employees support the business, with leadership comprising Dr. Dirk Pamperin (Chairman of the Management Board), Dr. Alexandra Pries and Andreas Ott as Managing Directors, and Dr. Ernst Susanek as Chairman of the Advisory Board. The acquisition of UroTec in 2010 added a urological care services arm to the legacy pharmaceutical core.

Name

APOGEPHA

Legal name

APOGEPHA Arzneimittel GmbH

Website

https://apogepha.de

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

1–10 employees

Short description

APOGEPHA Arzneimittel GmbH is a family-owned German pharmaceutical company in Dresden that develops and distributes pharmacy-exclusive prescription and OTC products for urology and uro-oncology, serving urologists, oncologists, and patients with BPH, prostatitis, bladder cancer, and neutropenia.

Ownership category

akta.pro rank

Product category

Urology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Urologic Oncology (HLAKAOAB)

Keywords

• Urology pharmaceuticals
• Bladder cancer treatment
• Prostate health products
• Intravesical immunotherapy
• Oncology supportive care

Headquarters

HQ city

Dresden

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Prescription Pharmaceuticals: Prescription medications for urology including APOPROSTAT forte for benign prostate enlargement, PROSTUROL suppositories for prostatitis, and BCG Apogepha for bladder cancer immunotherapy. Distributed pharmacy-exclusive through pharmacies.
2. Non-Prescription/OTC Products: Non-prescription products and food supplements including FEMALAC D-Mannose + Lactobacilli for urinary tract health. Available through pharmacies.
3. Supportive Oncology: Oncology supportive care products including Ryzneuta for neutropenia management. Discount agreements with health insurance providers such as Techniker Krankenkasse (TK).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

APOGEPHA develops, manufactures, and distributes pharmaceutical and dietary supplement products specialized in urology and uro-oncology. The portfolio includes prescription medications such as BCG Apogepha for intravesical bladder cancer immunotherapy, APOPROSTAT forte for benign prostate enlargement, PROSTUROL suppositories for prostatitis, and Ryzneuta (Efbemalenograstim alfa) for chemotherapy-induced neutropenia, alongside the FEMALAC D-Mannose dietary supplement for urinary tract health.

Product overview

APOGEPHA is a mid-sized family-owned pharmaceutical company specializing in urology and uro-oncology. The company develops, markets, and distributes innovative products including prescription pharmaceuticals (APOPROSTAT® forte for benign prostatic hyperplasia, PROSTUROL® for prostatitis, BCG Apogepha® 100 mg for bladder cancer immunotherapy) and dietary supplements (FEMALAC® for bladder and vaginal health). The portfolio also includes Ryzneuta® for neutropenia management in oncology. APOGEPHA reaches physicians and medical professionals through a qualified sales team with scientifically founded information to offer patients the best treatment options.

Differentiator

Problem solved

Functional benefit

Brands

• APOPROSTAT forte: Product for benign prostatic hyperplasia containing highly dosed phytosterol
• FEMALAC
• PROSTUROL
• Ryzneuta
• BCG Apogepha

Products and services

• APOPROSTAT forte

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Nordrhein-Westfälische Gesellschaft für Urologie e.V. (NRWGU)coreStrategic or Co-development Partner · 17 April 2026APOGEPHA sponsors the Dr. Richard Berges-Preis awarded annually at the NRWGU congress for outstanding achievements in ambulatory urology. Partnership supports recognition of innovation in outpatient urological care.
• Techniker Krankenkasse (TK)coreGTM or Marketing Partner · 1 December 2025Discount agreement (Rabattvereinbarung) between APOGEPHA and Techniker Krankenkasse for Efbemalenograstim alfa (Ryzneuta) effective December 1, 2025. The agreement enables covered access to the neutropenia treatment for TK insurees.
• Universität LeipzigminorStrategic or Co-development Partner · 1 November 2025APOGEPHA supports Deutschlandstipendien (Germany Scholarship) at University of Leipzig, promoting academic excellence and future talent in healthcare/pharmaceutical sciences. APOGEPHA has supported since 2012.
• Movember FoundationminorGTM or Marketing Partner · 1 November 2025APOGEPHA supports Movember initiative for prostate cancer awareness and men's health, participating in Movember Move Challenge 2025.
• Sächsische KrebsgesellschaftminorGTM or Marketing PartnerSupport for the 'Laufend gegen Krebs' initiative and Sonnenblumenlauf charity run. APOGEPHA Power Runners participate annually, donating 5 EUR per round completed.
• Dresdner MusikfestspieleminorGTM or Marketing PartnerAPOGEPHA acts as a promotional partner (Förderpartner) for the Dresdner Musikfestspiele, supporting cultural events in Dresden.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Amgen: Amgen's Neulasta (pegfilgrastim) and biosimilars dominate the G-CSF neutropenia market that APOGEPHA's Ryzneuta targets, making it the most direct competitive peer for the supportive oncology line.
• Ferring Pharmaceuticals: Ferring is a direct peer given its overlap in urology and reproductive health, plus its presence in bladder cancer supportive care — closely comparable to APOGEPHA's specialty urology/uro-oncology portfolio.
• Astellas Pharma: Astellas is a major direct competitor in urology with established franchises in overactive bladder (Vesicare/solifenacin) and prostate cancer (Xtandi), making it a highly comparable peer to APOGEPHA's urology/uro-oncology specialty focus.

Regional players

• Stada Arzneimittel: Stada is a German-headquartered mid-sized specialty and generics pharma — directly comparable to APOGEPHA in scale, German market footprint, and branded-generic/specialty mix.
• Berlin-Chemie (Menarini Group): Berlin-Chemie is a German mid-sized pharma within Menarini with a comparable specialty pharma model and German physician-channel distribution — a useful regional/scale peer to APOGEPHA.
• Dr. Pfleger Arzneimittel: Dr. Pfleger is a German mid-sized specialty pharma with a similar urology/OTC positioning and pharmacy-channel distribution model, making it a comparable German regional peer to APOGEPHA.

Emerging players

• UroGen Pharma: UroGen Pharma is an emerging player focused specifically on uro-oncology (e.g., Jelmyto for upper tract urothelial cancer), making it a comparable emerging specialty peer in APOGEPHA's uro-oncology niche.
• Photocure ASA: Photocure specializes in bladder cancer detection and treatment (Hexvix/Cysview), making it a directly comparable emerging specialty peer in the non-muscle-invasive bladder cancer segment where APOGEPHA's BCG product is positioned.

Broad incumbents

• Merck KGaA (Healthcare): Merck KGaA is a broad incumbent in oncology and urology-supportive care and is the historical manufacturer of BCG (BCG TICE/OncoTICE), making it a key comparand for both APOGEPHA's BCG and urology franchises.
• Johnson & Johnson (Janssen): Janssen has a broad urology and oncology portfolio (e.g., Erleada in prostate cancer) and is a broad incumbent whose scope, scale, and physician relationships overlap with APOGEPHA's target prescriber base.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• Facebookfacebook.com/apogepha
• LinkedInlinkedin.com/company/apogepha-arzneimittel-gmbh-dresden
• Instagraminstagram.com/apogepha

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about APOGEPHA